News

Who will get cancer treatment-induced cardiotoxicity?


 

AT THE HFSA ANNUAL SCIENTIFIC MEETING

References

“There is a real opportunity here to improve the care of cancer patients and prevent heart failure,” Dr. Lenihan concluded.

He reported receiving research support from Singulex, Millenium, and Acorda as well as serving as a consultant to Onyx and Roche.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Routine Oxygen at End of Life Typically Unhelpful
MDedge Hematology and Oncology
Studies Clash on Cardiac Effects of TKIs in Kidney Cancer
MDedge Hematology and Oncology
2-D Echo Is Inadequate Cardiomyopathy Screen in Childhood Cancer Survivors
MDedge Hematology and Oncology
Evidence Mounts on Heart Failure After Trastuzumab in Breast Cancer Survivors
MDedge Hematology and Oncology
Cardiac Toxicity Not Seen 25 Years after Breast Radiation
MDedge Hematology and Oncology
Guidelines issued on radiation-induced heart disease
MDedge Hematology and Oncology
Heart irradiation is lower with contemporary breast radiotherapy
MDedge Hematology and Oncology
Palliative care shortens ICU, hospital stays, review data show
MDedge Hematology and Oncology
Androgen-deprivation therapy linked to cardiac death
MDedge Hematology and Oncology
Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Hematology and Oncology